Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 6/20 | 0.35 |
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75974 | 0.89 | RIPK1 (0.33) | RIPK1DPP4 | |
| SCHEMBL2240055 | 0.83 | LMNA (0.44) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL1362536 | 0.81 | DPP4 (0.37) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL22518635 | 0.79 | PREP (0.34) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL22518585 | 0.79 | DPP4 (0.36) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL1592790 | 0.78 | LMNA (0.40) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL143131 | 0.78 | ATM (0.44) | RIPK1DPP4DPP8DPP9DPP7 | |
| SCHEMBL22518594 | 0.77 | HCRTR2 (0.32) | LMNAHSD17B10CYP2C19RIPK1DPP4 | |
| SCHEMBL25348697 | 0.77 | RIPK1 (0.32) | RIPK1DPP4 | |
| SCHEMBL29481524 | 0.76 | LMNA (0.44) | LMNAHSD17B10CYP2C19RIPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722298-B1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| EP-3722298-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | Oscotec Inc. (KR) | 2020-10-14 | — | — | EP | disclosed |
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | LMNA 2257/4885HSD17B10 4376/4885CYP2C19 4227/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | LMNA 1425/4885HSD17B10 3540/4885CYP2C19 2475/4885 |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | LMNA 4312/4885HSD17B10 1697/4885CYP2C19 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.